Company: DNLI
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001628280-25-056361
Chunk: 57

Company: Denali Therapeutics Inc.
Filing Date: 2025-12-10
Form: 424B5
Chunk 57
---
us. Any representation to the contrary is a criminal offense.

#### The date of this prospectus is
<div align='center'>February 27, 2025</div>

#### .

<div align='center'>________________________________________</div>

### TABLE OF CONTENTS
|                                     |     | Page |
| ABOUT THIS PROSPECTUS               |     |    1 |
| THE COMPANY                         |     |    2 |
| RISK FACTORS                        |     |    3 |
| USE OF PROCEEDS                     |     |    4 |
| DESCRIPTION OF SECURITIES           |     |    5 |
| PLAN OF DISTRIBUTION                |     |    6 |
| LEGAL MATTERS                       |     |    7 |
| EXPERTS                             |     |    7 |
| WHERE YOU CAN FIND MORE INFORMATION |     |    7 |
| INCORPORATION BY REFERENCE          |     |    8 |

### ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission (the "SEC") as a "well-known seasoned issuer" as defined in Rule 405 under the Securities Act of 1933, as amended, using a "shelf" registration process. By using a shelf registration statement, we may sell securities from time to time and in one or more offerings as described in this prospectus. Each time that we offer and sell securities, we will provide a prospectus supplement to this prospectus that contains specific information about the securities being offered and sold and the specific terms of that offering and, to the extent appropriate, any updates to the information about us contained in this prospectus. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement may also add, update or change information contained or incorporated by reference in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement, you should rely on the prospectus supplement. Before purchasing any securities, you should carefully read both this prospectus and the applicable prospectus supplement, together with the additional information described under the heading "Where You Can Find More Information" and "Incorporation by Reference."

We have not authorized anyone to provide you with any information or to make any representations other than those contained or incorporated by reference in this prospectus, any applicable prospectus supplement or